as of 11-16-2026 2:18pm EST
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
| Founded: | 1958 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 61.6B | IPO Year: | 1999 |
| Target Price: | $113.39 | AVG Volume (30 days): | 4.4M |
| Analyst Decision: | Buy | Number of Analysts: | 30 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.61 | EPS Growth: | -73.74 |
| 52 Week Low/High: | $74.66 - $107.69 | Next Earning Date: | 11-04-2026 |
| Revenue: | $6,067,600,000 | Revenue Growth: | 11.55% |
| Revenue Growth (this year): | 12.23% | Revenue Growth (next year): | 9.84% |
| P/E Ratio: | 66.63 | Index: | |
| Free Cash Flow: | 1.3B | FCF Growth: | +77.08% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
CVP, TAVR
Avg Cost/Share
$104.25
Shares
619
Total Value
$64,530.75
Owned After
40,033.91
SEC Form 4
CVP,Strategy/Corp Development
Avg Cost/Share
$103.05
Shares
48,900
Total Value
$5,039,311.26
Owned After
22,798.253
SEC Form 4
Avg Cost/Share
$103.08
Shares
23,100
Total Value
$2,379,779.41
Owned After
112,761
CVP, TAVR
Avg Cost/Share
$85.65
Shares
619
Total Value
$53,017.35
Owned After
40,033.91
SEC Form 4
CVP, TAVR
Avg Cost/Share
$87.51
Shares
619
Total Value
$54,168.69
Owned After
40,033.91
SEC Form 4
SVP, Corporate Controller
Avg Cost/Share
$91.06
Shares
544
Total Value
$49,533.92
Owned After
14,868.41
SEC Form 4
CVP, EMEACLA
Avg Cost/Share
$89.98
Shares
2,644
Total Value
$237,907.12
Owned After
17,984
SEC Form 4
CVP, TMTT, Surgical & IHFM
Avg Cost/Share
$91.38
Shares
31,800
Total Value
$2,894,439.62
Owned After
44,324
CVP, JAPAC
Avg Cost/Share
$91.47
Shares
1,240
Total Value
$113,416.60
Owned After
20,293.558
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Lippis Daniel J. | EW | CVP, TAVR | Nov 10, 2026 | Sell | $104.25 | 619 | $64,530.75 | 40,033.91 | |
| BOBO DONALD E JR | EW | CVP,Strategy/Corp Development | Nov 9, 2026 | Sell | $103.05 | 48,900 | $5,039,311.26 | 22,798.253 | |
| Zovighian Bernard J | EW | CEO | Nov 9, 2026 | Sell | $103.08 | 23,100 | $2,379,779.41 | 112,761 | |
| Lippis Daniel J. | EW | CVP, TAVR | Oct 8, 2026 | Sell | $85.65 | 619 | $53,017.35 | 40,033.91 | |
| Lippis Daniel J. | EW | CVP, TAVR | Sep 11, 2026 | Sell | $87.51 | 619 | $54,168.69 | 40,033.91 | |
| Dahl Andrew M. | EW | SVP, Corporate Controller | Aug 31, 2026 | Sell | $91.06 | 544 | $49,533.92 | 14,868.41 | |
| Bruls Annette | EW | CVP, EMEACLA | Aug 28, 2026 | Sell | $89.98 | 2,644 | $237,907.12 | 17,984 | |
| Chopra Daveen | EW | CVP, TMTT, Surgical & IHFM | Aug 26, 2026 | Sell | $91.38 | 31,800 | $2,894,439.62 | 44,324 | |
| Markowitz Wayne | EW | CVP, JAPAC | Aug 26, 2026 | Sell | $91.47 | 1,240 | $113,416.60 | 20,293.558 |
SEC 8-K filings with transcript text
Nov 4, 2026 · 100% conf.
1D
-6.98%
$92.40
Act: +1.46%
5D
-7.86%
$91.52
20D
-3.23%
$96.12
2 ex-991q32026.htm
Document
Edwards Lifesciences Corporation
One Edwards Way · Irvine, CA USA · 92614
Phone: 949.250.2500 · www.edwards.com
Media: Eric Endicott, media@edwards.com
Investors: Gerianne Sarte, investor_relations@edwards.com
IRVINE, CA, November 4, 2026 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026.
Q3 Financial Highlights
•Q3 sales grew 10.5% to $1.72 billion1, constant currency2 sales grew 11.2%
•Q3 TAVR sales grew 8.0% to $1.24 billion1, constant currency2 sales grew 8.8%
•Q3 TMTT sales grew 44.0% to $207 million1,3, constant currency2 sales grew 45.6%3
•Q3 EPS of $0.531; adjusted2 EPS of $0.801 which grew 19% versus prior year
2026 Outlook
•Increasing total company sales2 growth guidance to approximately 11.5% from 10% to 11%
•Increasing TAVR sales2 growth guidance to 9.0% to 9.5% from 8% to 9%
•Increasing TMTT sales guidance to $780 to $790 million from $760 to $780 million
•Increasing adjusted EPS guidance to $2.97 to $3.05 from $2.95 to $3.05, growing 18% at midpoint versus prior year
•2026 performance and milestone achievements reinforce long-term durable growth
Recent Highlights
•PROGRESS trial marks turning point in the management of moderate AS
•Practice-changing data adding to Edwards’ body of structural heart clinical evidence presented at TCT
•Final TAVR NCD represents important step toward expanding access to timely, high-quality care
•U.S. approval of PASCAL Precision for tricuspid repair expands access to differentiated therapy
•U.S. approval of PASCAL Ace with Capture Clarity simplifies mitral device placement
•European approval of SAPIEN M3 RESILIA brings most advanced tissue treatment to patients
•U.S. approval of AUTUS addresses lifelong needs of pediatric patients with congenital heart disease
“We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us the confidence to raise our full-year outlook,” said Bernard Zovighian, CEO of Edwards Lifesciences. “Our focused structural heart strategy, coupled with disciplined execution, long-term investments in category-creating innovation, and commitment to science and technology advancements, enabled us to deliver significant progress for patients on several of our most important clinical, regulatory, policy and commercial priorities this quarter. As I reflect on 2026 so far, I am proud of what our teams have accomplished and how we are positioning Edwards for strong, sustainable growth over the long term.”
Transcatheter Aortic Valve Replacement (TAVR)
In the third quarter, the company reported TAVR sales of $1.2 billion, which increased 8.0% compared to the prior year, or 8.8% on a constant currency basis. Edwards’ growth rates were similar in the U.S. and outside of the U.S. Globally, procedural growth benefited from a heightened focus on TAVR and data supporting proactive disease management of severe aortic stenosis (AS). Exiting Q3, the company saw encouraging signs of procedure growth. After several quarters of modest share gains, Edwards is pleased with how its competitive position, supported by its differentiated SAPIEN platform, has contributed to year-to-date TAVR performance. Average selling prices were stable globally.
In the U.S., procedure growth continued to benefit from a heightened focus on TAVR therapy as the clinical community further incorporates into practice the meaningful evidence supporting proactive disease management. Edwards’ competitive position in the U.S. was stable sequentially and increased modestly year-over-year, enabled by strong adoption of its SAPIEN 3 Ultra RESILIA platform. During the quarter, the Centers for Medicare & Medicaid Services (CMS) released the final, updated national coverage determination (NCD) for TAVR. The updated policy represents an important step toward improving and expanding timely, high-quality access to care while reinforcing the value of the multidisciplinary heart team.
Outside of the U.S., the company continues to see strong adoption of its SAPIEN technology. In Europe, updated ESC and EACTS guidelines are helping shape clinical discussions around earlier intervention and proactive disease management, further reinforcing the role of TAVR across a broader patient population. In Japan, Edwards was encouraged by the growth and continued adoption of its SAPIEN 3 Ultra RESILIA platform. Also in Japan, Edwards secured new and dedicated reimbursement for the SAPIEN 3 Ultra RESILIA platform, which recognizes the value of its innovation and helped contribute to Japan’s strong performance in the quarter.
Transcatheter Mitral and Tricuspid Therapies (TMTT)
Third quarter TMTT sales of $207 million3 increased 44.0% compared to the prior year, or 45.6% on a constant currency basis. Results were driven by the
Jul 23, 2026 · 100% conf.
1D
-6.98%
$77.97
Act: -1.42%
5D
-7.87%
$77.22
20D
-3.17%
$81.16
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.e618d017.1785191050.3eb89881
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
Apr 23, 2026 · 100% conf.
1D
+3.47%
$82.48
Act: +5.44%
5D
+3.49%
$82.50
Act: +4.74%
20D
+2.76%
$81.92
Act: +4.37%
2 ex-991q12026.htm
Document
Edwards Lifesciences Corporation
One Edwards Way · Irvine, CA USA · 92614
Phone: 949.250.2500 · www.edwards.com
Media: Amy Meshulam, media@edwards.com
Investors: Gerianne Sarte, investor_relations@edwards.com
IRVINE, CA, April 23, 2026 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2026.
Highlights and Outlook
•Q1 sales grew 16.7% to $1.65 billion1, constant currency2 sales grew 12.7%
•Q1 TAVR sales grew 14.4% to $1.20 billion1; constant currency2 sales grew 11.0%
•Q1 TMTT sales of $173 million1,3, driven by repair and replacement therapies
•Q1 EPS of $0.661; adjusted2 EPS of $0.781
•Raising FY 2026 constant currency2 sales growth guidance to 9% to 11% from 8% to 10%
•Raising FY 2026 adjusted2 EPS guidance midpoint; new range of $2.95 to $3.05 from $2.90 to $3.05
•Renewed clinical focus on proactive disease management with differentiated SAPIEN TAVR
•Completed $500 million Accelerated Share Repurchase
“Building on a year in 2025 marked by solid financial performance and strategic progress, we delivered another strong quarter in Q1, achieving 12.7% sales growth, which reflects the impact and durability of our focused strategy. We remain dedicated to solving large, urgent and complex patient needs and pursuing unique opportunities to innovate and lead in structural heart disease,” said Bernard Zovighian, Edwards’ CEO. “Based on our first quarter performance, we are raising our financial guidance for 2026. We continue to pursue additional meaningful growth opportunities across our portfolio, and our financial strength and strategic clarity give us confidence in the future.”
Transcatheter Aortic Valve Replacement (TAVR)
In the first quarter, the company reported TAVR sales of $1.2 billion, which grew 14.4% compared to the prior year, or 11.0% on a constant currency basis. SAPIEN growth in the U.S. was healthy, and it was even faster outside of the U.S. Edwards’ global competitive position in the first quarter increased slightly year-over-year mainly due to the exit of a competitor in Europe. Average selling prices were stable globally. Based on Edwards’ first quarter TAVR performance, the company is raising its full-year 2026 TAVR sales growth guidance to 7% to 9% from 6% to 8%.
Recent clinical trial results on long-term TAVR performance continue to support patient treatment with SAPIEN TAVR. The company is encouraged by the broader momentum that the EARLY TAVR study data has generated across the clinical community for both symptomatic and asymptomatic patients. There has been a shift toward proactive disease management, with an increased focus on evaluation and intentional referral of patients with severe aortic stenosis earlier in the disease pathway. This evolution in patient management, combined with a large and growing body of long-term SAPIEN outcomes data, reinforces the company’s confidence in the durable, multi-year growth opportunity ahead. Later this year, results of the PROGRESS trial studying patients with moderate AS will be presented at the TCT conference.
In the U.S., the Centers for Medicare & Medicaid Services (CMS) is conducting the process to reconsider the National Coverage Determination (NCD) for TAVR. This decision has the potential to improve timely access to lifesaving TAVR therapy. In Europe, first quarter results demonstrated continued strong commercial execution and sustained physician demand for the SAPIEN platform. Updated guidelines from the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery are reshaping clinical discussions around proactive disease management and reinforcing the role of TAVR for a broader patient population. Outside of Europe, sales growth was strong across multiple geographies, including Japan, driven by procedural growth and adoption of our SAPIEN 3 Ultra RESILIA platform.
Transcatheter Mitral and Tricuspid Therapies (TMTT)
First quarter TMTT sales of $173 million were driven by the company’s unique portfolio of repair and replacement therapies to treat mitral and tricuspid diseases. Globally, mitral and tricuspid procedures grew in the estimated double digits, with Edwards’ sales growing at a higher rate.
In tricuspid, at the recent American College of Cardiology (ACC) scientific session, two-year TRISCEND II data were presented, demonstrating significantly lower all-cause mortality with EVOQUE when accounting for patient crossover. The company continues to increase patient access to transcatheter tricuspid valve replacement and drive further adoption of EVOQUE by expanding into new centers.
Adoption of Edwards’ PASCAL transcatheter edge-to-edge repair (TEER) technology continues to increase, driven by physician enthusiasm for its unique design and differentiated outcomes, and underscored by the significant needs of these patients
See how EW stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "EW Edwards Lifesciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.